Trials that use: Risk difference
New to this method? Read the tutorial →
4,772 results
- Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01125046).
- Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection: Complete Statistical AnalysisIndependent statistical analysis of Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03167411).
- BFPSIndependent statistical analysis of Home Based Peer Support Program for Mothers With Low Breastfeeding Self-efficacy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BGIndependent statistical analysis of Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01727895).
- BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size…
- BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis: Complete Statistical AnalysisIndependent statistical analysis of BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01296932).
- BIANCAIndependent statistical analysis of Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- BiBETIndependent statistical analysis of Optimized Biventricular Pacing Allograft Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01290822).
- BIBSIndependent statistical analysis of Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02188459).
- Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine: Complete Statistical AnalysisIndependent statistical analysis of Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04538040).
- Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT: Complete Statistical AnalysisIndependent statistical analysis of Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation: Complete Statistical AnalysisIndependent statistical analysis of Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy (NRT): Complete Statistical AnalysisIndependent statistical analysis of Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy (NRT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00326781).
- BIO|CONCEPT.Renamic Neo Study: Complete Statistical AnalysisIndependent statistical analysis of BIO|CONCEPT.Renamic Neo Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04350008).
- Bioavailability and Safety Study Comparing Two Dose Levels of AMZ001 and One Dose Level of Diclofenac Sodium 1% Gel in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of Bioavailability and Safety Study Comparing Two Dose Levels of AMZ001 and One Dose Level of Diclofenac Sodium 1% Gel in Healthy Participants: primary endpoint results, effect estimate with…
- BioButton Among Nursing Home Residents: Complete Statistical AnalysisIndependent statistical analysis of BioButton Among Nursing Home Residents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06665685).
- BioCSI-2Independent statistical analysis of Biomarkers of Cockroach Sublingual Immunotherapy 2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01380327).
- Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328): Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328): primary endpoint results, effect estimate with confidence interval,…
- Bioequivalence of Pramipexole Extended Release (PPX ER) 1.5mg x 1 Tablet Once Daily (q.d.) vs. PPX ER 0.375mg x 4 Tablets Under Fasted and Fed Conditions in Japanese Healthy Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence of Pramipexole Extended Release (PPX ER) 1.5mg x 1 Tablet Once Daily (q.d.) vs. PPX ER 0.375mg x 4 Tablets Under Fasted and Fed Conditions in Japanese…
- Bioequivalence of TF3 and TF2 and Effect of Food on the PK of Tepotinib: Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence of TF3 and TF2 and Effect of Food on the PK of Tepotinib: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bioequivalence of Two Different Capsule Types of Dabigatran: Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence of Two Different Capsule Types of Dabigatran: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01290757).
- Bioequivalence Study of Esomeprazole 20 Milligram (mg) Delayed-Release Capsules in Healthy Adult Participants: Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence Study of Esomeprazole 20 Milligram (mg) Delayed-Release Capsules in Healthy Adult Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Bioequivalence Study of Paracetamol With Oral Single Dose Administration in Healthy Adult Subjects Under Fasting Conditions: Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence Study of Paracetamol With Oral Single Dose Administration in Healthy Adult Subjects Under Fasting Conditions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant Use: Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant Use: primary endpoint results, effect…
- BIOGUIDE-XIndependent statistical analysis of Performance and Safety of Biology-Guided Radiotherapy Using the RefleXion Medical Radiotherapy System (BIOGUIDE-X): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Biomarkers in First Episode Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Biomarkers in First Episode Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02033382).
- Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor: Complete Statistical AnalysisIndependent statistical analysis of Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Bipolar Ventricular Tachycardia (VT) Study: Complete Statistical AnalysisIndependent statistical analysis of Bipolar Ventricular Tachycardia (VT) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02374476).
- BIRCHIndependent statistical analysis of A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with…
- Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- BK Treatment Study: Complete Statistical AnalysisIndependent statistical analysis of BK Treatment Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01034176).
- BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent: Complete Statistical AnalysisIndependent statistical analysis of BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults: Complete Statistical AnalysisIndependent statistical analysis of BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts: Complete Statistical AnalysisIndependent statistical analysis of Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia: Complete Statistical AnalysisIndependent statistical analysis of Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BLOCk-CTIIndependent statistical analysis of Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission: Complete Statistical AnalysisIndependent statistical analysis of Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BLUESIndependent statistical analysis of Better Lithotripsy and Ureteroscopy Evaluation of Stenting (BLUES): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05026710).
- BMS 247550 to Treat Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of BMS 247550 to Treat Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00030992).
- BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT): Complete Statistical AnalysisIndependent statistical analysis of BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…